Trial Profile
Phase I dose-escalating trial of hepcidin [LJPC-401] in patients at risk of iron overload
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2018
Price :
$35
*
At a glance
- Drugs Hepcidin (Primary)
- Indications Iron overload
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors La Jolla Pharmaceutical Company
- 08 Aug 2018 According to a La Jolla Pharmaceutical Company media release, data from this study were presented at the European Hematology Association (EHA), June 2018.
- 17 May 2018 According to a La Jolla Pharmaceutical Company media release, data from this study will be presented at the European Hematology Association (EHA), June 2018.
- 07 Sep 2016 Results published in La Jolla media release.